ArticleFrontiers in oncology2023

Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy.

Yulong Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.